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ABSTRACT 44 
Objective 45 
To show how a simple Bayesian analysis method can be used to improve the evidence base 46 
in patient populations where recruitment and retention are challenging.  47 
Methods 48 
A Bayesian conjugate analysis method was applied to binary data from the Thermal testing 49 
in Bone Pain (TiBoP) study: a prospective diagnostic accuracy/predictive study in patients 50 
with cancer-induced bone pain (CIBP).   This study aimed to evaluate the clinical utility of a 51 
simple bedside tool to identify who was most likely to benefit from palliative radiotherapy 52 
(XRT) for CIBP.  53 
Results 54 
Recruitment and retention of patients was challenging due to the frail population, with only 55 
27 patients available for the primary analysis. The Bayesian method allowed us to make use 56 
of prior work done in this area and combine it with the TiBoP data to maximise the 57 
informativeness of the results. Positive and negative predictive values were estimated with 58 
greater precision, and interpretation of results was facilitated by use of direct probability 59 
statements. In particular, there was only 7% probability that the true positive predictive 60 
value was above 80%.  61 
Conclusions 62 
Several advantages of using Bayesian analysis are illustrated in this article. The Bayesian 63 
method allowed us to gain greater confidence in our interpretation of the results despite 64 
the small sample size by allowing us to incorporate data from a previous similar study. We 65 
suggest that this method is likely to be useful for the analysis of small diagnostic or 66 
predictive studies when prior information is available. 67 
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 72 
INTRODUCTION 73 
 74 
The TiBoP study was concerned with improving outcomes for patients with cancer-induced 
bone pain (CIBP). CIBP is a consequence of metastases to bone; and can have a major 
impact on day-to-day function and quality of life.[1] Currently, the gold standard treatment 
is palliative radiotherapy (XRT), although only approximately half of patients will achieve 
satisfactory pain relief, and this may take up to six weeks to work properly.[2,3]  
 75 
Somatosensory testing, used to define pain mechanisms in individual patients, has shown 76 
some promise in predicting treatment response in neuropathic pain.[4] Our previous pilot 77 
work demonstrated sensory changes in CIBP, with alterations in skin sensation overlying the 78 
area of CIBP.[1] This pilot work suggested that altered thermal sensitivity on the skin 79 
overlying the site of painful bone metastases might have value in predicting an increased 80 
likelihood of a good outcome from XRT.[5]  81 
 82 
Therefore, the Thermal testing in Bone Pain (TiBoP) study was carried out to assess the 83 
performance of a simple thermal sensitivity measure that could be used by non-specialists 84 
in the community, to identify who was most likely to get analgesic benefit from XRT for 85 
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CIBP. The study faced challenges with recruitment and retention of patients, and the final 86 
study sample size was small. Conducting research in palliative care can be challenging due to 87 
the frailty of the patient population making it difficult to establish a robust evidence base. 88 
There is need for using innovative methods to deal with this challenging research 89 
environment. 90 
 91 
 92 
This short report shows how a simple Bayesian analysis can be used to maximise the value 93 
of small diagnostic studies by allowing previous data to bolster the results.  94 
 
 
METHODS 95 
 96 
The TiBoP study 97 
The TiBoP study was a prospective exploratory study, carried out in two centres (Edinburgh 98 
and Dundee) and approved by South Central - Oxford C Research Ethics Committee 99 
No:16/SC/0260.  All patients gave written informed consent to take part in the study. 100 
 101 
The thermal sensitivity tool evaluated in this study involved using warm (40°C) and cool 102 
(25°C) thermal rollers (Rolltemp, Somedic, Sweden, CE marked) to assess the thermal 103 
sensitivity of the skin overlying the painful bone metastasis in comparison to a 104 
corresponding unaffected (control) area. 105 
 106 
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Eligible patients were adults (aged 18 or older) scheduled for palliative XRT for treatment of 107 
CIBP. A convenience sample of eligible patients were recruited between October 2016 and 108 
May 2018; and all were  tested using the thermal sensitivity tool prior to receiving XRT. The 109 
primary endpoint was pre-specified to be worst pain score at six weeks post-XRT, using the 110 
Brief Pain Inventory (BPI) questionnaire. Specifically, the primary endpoint was defined as 111 
either (i) a 30% or higher reduction in worst pain score (Q3 of the BPI questionnaire), or (ii) a 112 
worst pain score of zero at six weeks. This mirrored the endpoint for pain response used in 113 
our previous study.[5,6] Our hypothesis was that patients experiencing “abnormal 114 
sensitivity” based on the thermal sensitivity test were more likely to achieve a response to 115 
XRT (i.e. pain reduction).  116 
 117 
Statistical methods 118 
 119 
The statistical analysis was concerned with making inference about the true values of the 120 
sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of 121 
the thermal sensitivity score with respect to experiencing a response to XRT. In practice, 122 
there were two components to the thermal sensitivity test: a test involving a warm roller 123 
and a separate test involving a cool roller. If patients reported abnormal sensitivity for both 124 
tests then the overall score was assumed to be “abnormal”. A separate analysis was 125 
conducted under the assumption that any of the two tests needed to be “abnormal” for the 126 
overall score to be “abnormal”. 127 
 128 
The primary analysis was conducted in a Bayesian framework, using Bayes’ theorem.[7-9] 129 
The key to understanding Bayesian analysis is that we begin with prior information 130 
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regarding the parameters of interest (e.g. sensitivity and specificity); and then we use Bayes’ 131 
theorem to update our prior information based on observed data.[9] In the case of the 132 
TiBoP study, prior information about the likely value of the proportions of interest was 133 
gathered from a previous pilot study conducted as part of an MD thesis.[6] In Bayesian 134 
analysis, prior information or beliefs are usually expressed as a range of possible values 135 
through specification of a probability distribution.[9] In our case, a beta distribution was 136 
used for the prior and binomial distribution to model the binary thermal sensitivity test data 137 
(e.g. “abnormal” response or not).  138 
 139 
After combining the model for the observed data with the model for the prior information 140 
using Bayes’ theorem, we obtain a “posterior distribution”, which gives us a probability 141 
distribution for the probability of the proportions given the observed data, which is what we 142 
are really interested in. In our case, we get a posterior distribution that has a beta 143 
distributional form just like our prior distribution. Formally, this is called a “conjugate 144 
analysis” [7] and we say that the beta distribution is “conjugate” to the binomial 145 
distribution.  146 
 147 
R software [10] was used to perform the analysis. Graphs of posterior distributions were 148 
generated for all diagnostic test statistics of interest (i.e. probability distributions for the 149 
true parameters of interest: NPV, PPV, sensitivity, specificity etc.), while posterior means 150 
and 95% highest posterior density (HPD) credible intervals were calculated to show the 151 
likely range of values for the true parameter (e.g. true NPV).  152 
 153 
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A specific (informative) prior was pre-specified based on the previous pilot study, but we 154 
also checked the sensitivity of the results to this prior by using a (i) a weakly informative 155 
prior and (ii) a flat completely uninformative prior (Beta(1,1)). This allowed us to compare 156 
our results with models for which the observed TiBoP study data dominated.  157 
 158 
Results were compared to the classical (frequentist) approach of calculating 95% confidence 159 
intervals around parameters without utilizing prior data. 160 
 161 
Further details of the statistical analysis are provided in the online supplementary file along 162 
with a mini-literature review suggesting that the use of this method is very uncommon in 163 
practice. 164 
 165 
RESULTS 166 
Forty patients were recruited to the study between October 2016 and April 2018 from two 167 
locations (34 from Edinburgh and six from Dundee, United Kingdom). Twenty-seven patients 168 
(67%) completed the primary outcome assessment at six weeks.  169 
 170 
Of the 27 patients recording primary outcome data, the mean age was 65 (SD 9.5, range 43 171 
to 84). Eleven patients (41%) were female. Thirteen had a primary diagnosis of prostate 172 
cancer (48%), eight had breast cancer (30%) and the remaining six patients (22%) had 173 
various other types of cancer. 174 
 175 
Considering the comparison of patients with both abnormal thermal sensitivity tests 176 
compared to those with at least one normal, the observed sensitivity, specificity, PPV and 177 
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NPV of the thermal sensitivity score (with corresponding exact binomial 95% confidence 178 
intervals) were calculated as 9/15 (60%, 95% CI 32% to 84%), 5/12 (42%, 95% CI 15% to 179 
72%), 9/16 (56%, 95% CI 30% to 80%), and 5/11 (45%, 95% CI 17% to 77%) respectively. 180 
These 95% confidence intervals were computed using the standard classical method 181 
ignoring prior data. 182 
 183 
The observed results with classical confidence intervals suggest that thermal sensitivity 184 
score is a poor predictor of positive response to XRT. PPV and NPV are close to 50% and 185 
specificity is very low. Confidence intervals were very wide, so there was a great deal of 186 
uncertainty associated with the estimates when just considering the current study data. 187 
 188 
After using results from the previous pilot study to inform the prior distribution, Bayes’ 189 
Theorem was used to produce plots of the posterior distributions for each diagnostic test 190 
statistic (see Figure 1).  191 
 192 
The posterior mean PPV (95% credible interval) was 70% (57% to 83%), suggesting that it is 193 
unlikely that the true PPV for the thermal sensitivity tool is above 83%. Indeed, the 194 
probability that the true PPV is above 80% was only 7% ( ℙ(𝑃𝑃𝑉 > 0.80) = 0.07 ). This 195 
means that the thermal sensitivity test is unlikely to be useful in accurately identifying 196 
patients who will go on to get a positive response to XRT at six weeks. The credible interval 197 
upper bound is similar to the classical frequentist confidence interval of 80%, but note that 198 
the interval is much narrower since we have combined with the previous data (PPV 199 
estimated as 81%) to increase the precision of estimation. Using a flat non-informative prior 200 
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(i.e. ignoring the prior data we have), results in a credible interval from 33% to 77%, which is 201 
similar to that from the frequentist 95% CI as we might expect. 202 
 203 
For NPV, the posterior mean was 48%, but the 95% credible interval had a very wide range 204 
from 30% to 66% due to the low number of patients in this category. Note that this interval 205 
is also much narrower than the corresponding frequentist 95% confidence interval of 17% to 206 
77%. Indeed, it is true in general that precision of estimation will often be improved through 207 
using Bayesian methods, particularly if specific informative priors are used and the study 208 
sample size is small.  209 
 210 
To provide a more extreme example: only 3 patients had thermal test results which were 211 
both normal. Two of these did not show a positive response to XRT, and so the NPV under 212 
the “at least one abnormal” classification was calculated as 2/3 (67%). Naturally, the 213 
standard 95% CI for the NPV was extremely wide (9% to 99%). However, after combining 214 
with the prior information (NPV 3/4, 75%), the 95% HPD interval was 38% to 94%, which 215 
although still wide, does inform us that very high values of the NPV above 94% are unlikely. 216 
We can also calculate ℙ(𝑁𝑃𝑉 > 0.90) = 0.04 which supports this conclusion. 217 
 218 
In contrast, the PPV (“at least one abnormal” classification), was based on more substantial 219 
sample sizes (PPV was 14/24 (58%) for the current study and 28/38 (74%) in the previous 220 
study). In this example, the 95% HDP interval was 56% to 78% compared to a 95% CI of 57% 221 
to 87%. Thus, our interval upper bound reduces from 87% down to 78% with the addition of 222 
prior information. We can also calculate ℙ(𝑃𝑃𝑉 > 0.80) = 0.01, which shows there is only 223 
1% probability that the true PPV is above 80%. 224 
9
 225 
For the above examples, the estimates based on the prior information are not too 226 
inconsistent with those from the present study. If hypothetically, the prior PPV was only 3% 227 
(1/38), then the 95% HPD interval becomes substantially different, 15% to 36%, albeit the 228 
interval is still much narrower than the corresponding 95% CI.  229 
 230 
The Bayesian results suggested that the thermal sensitivity tool alone is unlikely to be useful 231 
in practice for identifying patients who experience a response to XRT treatment. This was 232 
despite the use of an informative prior distribution based on promising results from an 233 
earlier study.[5,6]  234 
 235 
Full analysis results are provided in a supplementary file. 236 
 237 
 238 
DISCUSSION 239 
Bayesian analysis has some advantages over classical analysis. In particular: 240 
 241 
(i) It makes full use of previous work done in the same area so that it informs the statistical 242 
analysis. The Bayesian argument is that no study happens in isolation, and that it makes 243 
sense to incorporate external information when performing statistical inference because 244 
scientific progress generally always involves building on what has been done before. 245 
(ii) In small studies, the informativeness of the results can be maximised through more 246 
precise estimates of diagnostic test measurements (e.g. NPV and PPV). 247 
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(iii) Interpretation of results is easier and more intuitive. For example, the true value lies 248 
within a 95% credible interval with 95% probability.  249 
(iv) Posterior distribution graphs of parameters can be generated from Bayesian analysis 250 
(see Figure 1) to provide helpful visual information regarding the likely true value. 251 
(v) In addition, direct probability statements can be made that are easier to interpret 252 
clinically.[11] As shown above, we can easily answer questions such as “What is the 253 
probability that the true negative predictive value is above 80%?” Whereas in classical 254 
analysis it is very difficult to answer such questions. 255 
(vi) Bayesian analysis is more ethical because it fully exploits the clinical experience of past 256 
patients to maximise the potential of a small sample size to generate meaningful 257 
results.[11] Even data from very small prior studies is not wasted and can contribute to 258 
the analysis.   259 
 260 
Bayesian analysis was particularly useful for the TiBoP example because data was available 261 
from a very similar previous study, the study was small (and so we could take full advantage 262 
of the improvement in precision resulting from incorporating prior data), and there was an 263 
ethical imperative to make maximal use of all data collected. These advantages more 264 
generally apply in studies in palliative care, where patients are frail, with life limiting disease 265 
and therefore it is especially important to ensure that precious data collected from patients 266 
is not wasted. In general patients are supportive of participating in clinical research, often 267 
for altruistic reasons, although naturally there may be burden placed on these patients 268 
when collecting data.[12]  269 
 270 
In the TiBoP study, there was a consistent gain in precision from using Bayesian methods: 271 
our 95% credible intervals were narrower than the corresponding 95% confidence intervals. 272 
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In some situations (e.g. in our NPV example), this enabled us to salvage data that may 273 
otherwise have been completely unusable due to the tiny sample size. However, there is a 274 
note of caution associated with this. As we saw in the PPV example, artificially changing the 275 
prior information led to a dramatic change in the values of the credible interval estimates. 276 
This was because we were using a specific informative prior to combine with the observed 277 
information, which places a high weight on prior information. This was justified in our case 278 
since the studies were very similar in design, with the same lead researchers and 279 
assessment approaches used for both studies, and the majority of patients recruited from 280 
the same centre (Edinburgh). However, it was still important for us to test the sensitivity of 281 
the results to the use of non-informative priors (see supplementary file). 282 
 283 
If on the other hand, the previous study was conducted under very different conditions, had 
a different patient population, or was more susceptible to bias, then less weight should have 
been placed on the prior information and it would have been necessary to use vague or 
non-informative priors for our primary analysis. However, collaterally we lose the advantage 
of improved precision from using Bayesian methods. 
 
Bayesian analysis may be less useful in circumstances which nullify some of the advantages 
listed above. For example, if our study has a large sample size with no similar previous 
studies, then finding suitable information to inform the prior distribution may be difficult 
and there may be little or no gain in precision from using a Bayesian approach. 
Nevertheless, some advantages of Bayesian analysis will still remain regardless of the 
context (e.g. the ability to make direct probability statements). 
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The methodology used in this study is particularly beneficial in settings where it is difficult to 
establish a robust evidence base (e.g. in frail populations or rare conditions) due to its ability 
to effectively assimilate prior data and enhance the value of information from small studies. 
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FIGURE 329 
 330 
 331 
Figure 1: Plots showing the posterior distributions for the diagnostic test parameters 332 
under the strategy of using “at least one test abnormal” as the diagnostic test marker to 333 
predict positive response. Solid line indicates specific prior, dashed line is weakly specific 334 
prior, and dotted line is uninformative prior. 335 
 336 
 337 
 338 
15
